Observational follow-up of the PROactive study: A 6-year update

Diabetes, Obesity and Metabolism

Volumn 16, Issue 1, 2014, Pages 63-74

  Erdmann, E ^a   Song, E ^b   Spanheimer, R ^c   van Troostenburg de Bruyn, A R ^d   Perez, A ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b TAKEDA PHARMACEUTICALS   (United States)

^c Takeda Pharmaceuticals International Inc   (United States)

^d Takeda Global Research and Development Centre (Europe) Ltd   (United Kingdom)

Author keywords

Diabetes mellitus; Pioglitazone; Rosiglitazone; Thiazolidinediones

Indexed keywords

PIOGLITAZONE; PLACEBO;

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; BLADDER CANCER; BREAST CANCER; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COLON CANCER; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DRUG INDUCED CANCER; FEMALE; FOLLOW UP; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY CANCER; LEG AMPUTATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; REVASCULARIZATION; SECONDARY PREVENTION; SKIN CANCER; UTERUS CANCER;

DIABETES MELLITUS; PIOGLITAZONE; ROSIGLITAZONE; THIAZOLIDINEDIONES;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84890561445     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12180     Document Type: Article

References (52)

1. Dormandy JA, Charbonnel B, Eckland DJ et al. PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro-Vascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
2. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Mouoles IK, Skene AM. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49: 1772-1780.
3. Wilcox R, Bousser MG, Betteridge DJ et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38: 865-873.
4. Wilcox R, Kupfer S. Erdmann E; PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J 2008; 155: 712-717.
5. Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572-2581.
6. Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-1573.
7. Davidson M, Meyer PM, Haffner S et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation 2008; 117: 2123-2130.
8. Nicholls SJ, Tuzcu EM, Wolski K et al. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. J Am Coll Cardiol 2011; 57: 153-159.
9. Ferrannini E, Betteridge DJ, Dormandy JA et al. High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive. Diabetes Obes Metab 2011; 13: 759-764.
10. Erdmann E, Wilcox R. Pioglitazone and mechanisms of CV protection. QJM 2010; 103: 213-228.
11. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR, PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009; 32: 187-202.
12. Erdmann E, Dormandy JA, Massi-Benedetti M, Spanheimer R. Pioglitazone and bladder cancer-Authors' reply. Lancet 2011; 378: 1544-1545.
13. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A, PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004; 27: 1647-1653.
14. US Food and Drug Administration. Guidance for industry: Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Published December 2008. Available from URL: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed March 2012.
15. Joffe HV, Parks MH, Temple R. Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus. Rev Endocr Metab Disord 2010; 11: 21-30.
16. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus [Draft]. Published September 2011. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/10/WC500115945.pdf. Accessed March 2012.
17. Betteridge DJ, DeFronzo RA, Chilton RJ. PROactive: time for a critical appraisal. Eur Heart J 2008; 29: 969-983.
18. Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473000 patients using the National Health Insurance database in Taiwan. Drug Saf 2009; 32: 675-690.
19. Pantalone KM, Kattan MW, Yu C et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 2009; 46: 145-154.
20. Tzoulaki I, Molokhia M, Curcin V et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009; 339: b4731.
21. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 2011; 342: d1309.
22. Schernthaner G, Chilton RJ. Cardiovascular risk and thiazolidinediones-what do meta-analyses really tell us? Diabetes Obes Metab 2010; 12: 1023-1035.
23. Erdmann E, Charbonnel B, Wilcox RG et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007; 30: 2773-2778.
24. Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008; 29: 12-20.
25. Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L. PROactive Investigators. Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11). Atherosclerosis 2009; 202: 272-281.
26. Grote VA, Becker S, Kaaks R. Diabetes mellitus type 2 - an independent risk factor for cancer? Exp Clin Endocrinol Diabetes 2010; 118: 4-8.
27. van Staa TP, Patel D, Gallagher AM, de Bruin ML. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 2012; 55: 654-665.
28. Matsumoto K, Irie A, Satoh T, Kuruma H, Arakawa T, Baba S. Occupational bladder cancer: from cohort study to biologic molecular marker. Med Sci Monit 2005; 11: RA311-RA315.
29. Azoulay L, Yin H, Filion KB et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012; 344: e3645.
30. Lewis JD, Ferrara A, Peng T et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-922.
31. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012; 55: 1953-1962.
32. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012; 35: 278-280.
33. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2012; 55: 1462-1472.
34. European Medicines Agency. European Medicines Agency clarifies opinion on pioglitazone and the risk of bladder cancer. Positive benefit-risk balance confirmed as second and third line treatment. Press release 21 October, 2011. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/10/WC500116936.pdf. Accessed March 2012.
35. US Food and Drug Administration. Actos (pioglitazone): Ongoing Safety Review - Potential Increased Risk of Bladder Cancer. Updated 4 August, 2011. Available from URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm226257.htm. Accessed March 2012.
36. Li W, Macdonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 2013; 75: 254-259.
37. Ferrara A, Lewis JD, Quesenberry CP Jr et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011; 34: 923-929.
38. Govindarajan R, Ratnasinghe L, Simmons DL et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007; 25: 1476-1481.
39. Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 485-492.
40. Annicotte JS, Iankova I, Miard S et al. Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol 2006; 26: 7561-7574.
41. Gottfried E, Rogenhofer S, Waibel H et al. Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids. Cancer Chemother Pharmacol 2011; 67: 117-126.
42. Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO. Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer 2002; 102: 258-261.
43. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005; 161: 147-152.
44. Calton BA, Chang SC, Wright ME et al. History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 2007; 18: 493-503.
45. Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 2009; 124: 1398-1403.
46. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Cohort Study of Pioglitazone and Bladder Cancer in Patients with Type II Diabetes. Updated 17 August 2012. Available from URL: http://www.encepp.eu/encepp/viewResource.htm?id=2718. Accessed 2 October 2012.
47. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012; 107: 46-52.
48. Lai SW, Liao KF, Chen PC, Tsai PY, Hsieh DP, Chen CC. Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. Clin Lung Cancer 2012; 13: 143-148.
49. Lewis JD, Capra AM, Achacoso NS et al. Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus. Gastroenterology 2008; 135: 1914-1923.
50. Oliveria SA, Koro CE, Yood MU, Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metabolic Syndr Clin Res Rev 2008; 2: 47-57.
51. Ramos-Nino ME, MacLean CD, Littenberg B. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med 2007; 5: 17.
52. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol 2012; 23: 1771-1780.